Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?

Merck appears to be the big winner in the Medicare Part D formulary placement battle for cholesterol-lowering therapies, according to an analysis of plan formularies conducted by the "The Pink Sheet."